Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human normal immunoglobulin is a plasma-derived, polyvalent human IgG preparation administered intravenously; the Aalborg recurrent pregnancy loss study used the 10% IVIg product **Privigen**. It contains a broad spectrum of intact IgG antibodies and has pleiotropic immunomodulatory activity, including antibody-mediated neutralisation and opsonisation, rather than a single defined molecular target. At Aalborg University Hospital, Privigen was investigated with oral prednisolone in a completed randomised, double-blind, placebo-controlled phase 2 trial for unexplained recurrent pregnancy loss after assisted reproductive technology; the IVIg component was administered around embryo transfer and through early pregnancy. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT04701034/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human normal immunoglobulin (CSL Limited).